2015 Q1 Form 10-K Financial Statement
#000114420415015698 Filed on March 12, 2015
Income Statement
| Concept | 2015 Q1 | 2014 Q4 | 2014 |
|---|---|---|---|
| Revenue | $477.0K | $870.0K | $2.818M |
| YoY Change | -67.81% | -43.87% | -42.17% |
| Cost Of Revenue | $514.0K | $480.0K | $2.034M |
| YoY Change | -17.76% | -30.43% | -10.91% |
| Gross Profit | -$37.00K | $390.0K | $784.0K |
| YoY Change | -104.32% | -54.65% | -69.73% |
| Gross Profit Margin | -7.76% | 44.83% | 27.82% |
| Selling, General & Admin | $2.987M | $3.580M | $15.74M |
| YoY Change | -21.7% | -11.17% | 25.01% |
| % of Gross Profit | 917.95% | 2007.4% | |
| Research & Development | $1.352M | $1.260M | $8.744M |
| YoY Change | -47.54% | -28.81% | 110.39% |
| % of Gross Profit | 323.08% | 1115.31% | |
| Depreciation & Amortization | $80.00K | $80.00K | $163.0K |
| YoY Change | 33.33% | 33.33% | 0.62% |
| % of Gross Profit | 20.51% | 20.79% | |
| Operating Expenses | $4.853M | $4.840M | $24.48M |
| YoY Change | -24.08% | -16.7% | 38.61% |
| Operating Profit | -$4.890M | -$4.450M | -$23.70M |
| YoY Change | -11.65% | -10.1% | 57.22% |
| Interest Expense | $301.0K | -$330.0K | $1.409M |
| YoY Change | -14.49% | -23.26% | -66.99% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$306.0K | -$10.00K | -$1.385M |
| YoY Change | -25.91% | -50.0% | -90.23% |
| Pretax Income | -$5.196M | -$4.780M | -$25.08M |
| YoY Change | -12.64% | -11.15% | -14.25% |
| Income Tax | $16.00K | $10.00K | $12.00K |
| % Of Pretax Income | |||
| Net Earnings | -$5.212M | -$4.790M | -$25.10M |
| YoY Change | -12.67% | -11.13% | -14.23% |
| Net Earnings / Revenue | -1092.66% | -550.57% | -890.53% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$4.568B | -$5.398B | -$30.98B |
| COMMON SHARES | |||
| Basic Shares Outstanding | 78.15M shares | 42.40M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2015 Q1 | 2014 Q4 | 2014 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $13.19M | $6.300M | $6.300M |
| YoY Change | -3.79% | -64.08% | -64.08% |
| Cash & Equivalents | $13.19M | $6.300M | $6.300M |
| Short-Term Investments | |||
| Other Short-Term Assets | $110.0K | $150.0K | $150.0K |
| YoY Change | -45.0% | -34.78% | -34.78% |
| Inventory | $1.750M | $1.924M | $1.924M |
| Prepaid Expenses | $109.0K | $150.0K | |
| Receivables | $719.0K | $635.0K | $635.0K |
| Other Receivables | $280.0K | $17.00K | $359.0K |
| Total Short-Term Assets | $16.04M | $9.368M | $9.368M |
| YoY Change | -6.79% | -56.64% | -56.63% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $584.0K | $622.0K | $622.0K |
| YoY Change | -6.41% | -4.6% | -4.31% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | $400.0K | $752.0K | |
| YoY Change | -52.21% | -11.74% | |
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $1.100M | $1.469M | $1.469M |
| YoY Change | -34.13% | -14.09% | -14.09% |
| Total Long-Term Assets | $1.682M | $2.091M | $2.091M |
| YoY Change | -26.68% | -11.47% | -11.77% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $16.04M | $9.368M | $9.368M |
| Total Long-Term Assets | $1.682M | $2.091M | $2.091M |
| Total Assets | $17.72M | $11.46M | $11.46M |
| YoY Change | -9.13% | -52.19% | -52.19% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $670.0K | $910.0K | $909.0K |
| YoY Change | -52.48% | -43.83% | -43.89% |
| Accrued Expenses | $958.0K | $993.0K | $3.561M |
| YoY Change | 31.77% | 12.08% | 14.5% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $3.910M | $3.810M | $0.00 |
| YoY Change | 86.19% | 222.88% | -100.0% |
| Total Short-Term Liabilities | $7.502M | $8.473M | $8.473M |
| YoY Change | -0.08% | 38.36% | 38.45% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $4.140M | $5.090M | $5.086M |
| YoY Change | -46.58% | -40.75% | -40.79% |
| Other Long-Term Liabilities | $700.0K | $690.0K | $687.0K |
| YoY Change | 9.38% | 13.11% | 12.62% |
| Total Long-Term Liabilities | $4.837M | $5.773M | $5.773M |
| YoY Change | -42.31% | -37.27% | -37.25% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $7.502M | $8.473M | $8.473M |
| Total Long-Term Liabilities | $4.837M | $5.773M | $5.773M |
| Total Liabilities | $12.34M | $14.25M | $14.25M |
| YoY Change | -22.36% | -7.05% | -7.07% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$112.6M | -$107.4M | |
| YoY Change | 27.57% | 30.49% | |
| Common Stock | $118.0M | $104.6M | |
| YoY Change | 28.41% | 15.03% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $5.385M | -$2.787M | -$2.787M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $17.72M | $11.46M | $11.46M |
| YoY Change | -9.13% | -52.19% | -52.19% |
Cashflow Statement
| Concept | 2015 Q1 | 2014 Q4 | 2014 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$5.212M | -$4.790M | -$25.10M |
| YoY Change | -12.67% | -11.13% | -14.23% |
| Depreciation, Depletion And Amortization | $80.00K | $80.00K | $163.0K |
| YoY Change | 33.33% | 33.33% | 0.62% |
| Cash From Operating Activities | -$4.620M | -$5.090M | -$19.36M |
| YoY Change | 24.53% | 44.19% | 87.98% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $1.000K | -$20.00K | $133.0K |
| YoY Change | -92.31% | -80.0% | -34.16% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$10.00K | $10.00K | $47.00K |
| YoY Change | -50.0% | -125.0% | -167.14% |
| Cash From Investing Activities | -$10.00K | -$20.00K | -$86.00K |
| YoY Change | -66.67% | -85.71% | -77.13% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $12.50M | $7.400M | -$9.535M |
| YoY Change | -58.33% | ||
| Debt Paid & Issued, Net | $891.0K | $1.148M | |
| YoY Change | |||
| Cash From Financing Activities | 11.56M | 6.450M | 8.272M |
| YoY Change | -14550.0% | -33.91% | -45.3% |
| NET CHANGE | |||
| Cash From Operating Activities | -4.620M | -5.090M | -19.36M |
| Cash From Investing Activities | -10.00K | -20.00K | -86.00K |
| Cash From Financing Activities | 11.56M | 6.450M | 8.272M |
| Net Change In Cash | 6.930M | 1.340M | -11.18M |
| YoY Change | -281.41% | -78.0% | -351.32% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$4.620M | -$5.090M | -$19.36M |
| Capital Expenditures | $1.000K | -$20.00K | $133.0K |
| Free Cash Flow | -$4.621M | -$5.070M | -$19.50M |
| YoY Change | 24.12% | 47.81% | 85.63% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2014Q2 | dei |
Entity Public Float
EntityPublicFloat
|
90786938 | USD |
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
58000 | USD | |
| CY2014 | us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
57000 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
10490000 | USD | |
| CY2013 | us-gaap |
Operating Expenses
OperatingExpenses
|
17663000 | USD |
| CY2012 | us-gaap |
Operating Expenses
OperatingExpenses
|
20045000 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8827000 | USD | |
| CY2013 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-15073000 | USD |
| CY2013Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2013Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
33983346 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
125000000 | shares |
| CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2014Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2013 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
2283000 | USD |
| CY2012 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
2849000 | USD |
| us-gaap |
Gross Profit
GrossProfit
|
1663000 | USD | |
| CY2013 | us-gaap |
Gross Profit
GrossProfit
|
2590000 | USD |
| CY2012 | us-gaap |
Gross Profit
GrossProfit
|
2500000 | USD |
| CY2013 | us-gaap |
Royalty Expense
RoyaltyExpense
|
918000 | USD |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3315000 | USD | |
| CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4156000 | USD |
| CY2012 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3988000 | USD |
| us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
2647000 | USD | |
| CY2013 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
3616000 | USD |
| CY2012 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
2174000 | USD |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4528000 | USD | |
| CY2013 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8973000 | USD |
| CY2012 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
13883000 | USD |
| CY2012 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17545000 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
273000 | USD | |
| CY2013 | us-gaap |
Interest Expense
InterestExpense
|
4268000 | USD |
| CY2012 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
14000 | USD |
| CY2012 | us-gaap |
Interest Expense
InterestExpense
|
1238000 | USD |
| us-gaap |
Nonoperating Gains Losses
NonoperatingGainsLosses
|
-226000 | USD | |
| CY2013 | us-gaap |
Nonoperating Gains Losses
NonoperatingGainsLosses
|
-9909000 | USD |
| CY2012 | us-gaap |
Nonoperating Gains Losses
NonoperatingGainsLosses
|
1200000 | USD |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-9326000 | USD | |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-29250000 | USD |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-17583000 | USD |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
10000 | USD | |
| CY2013 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
8000 | USD |
| CY2012Q4 | nspr |
Royalty Fee Percent Of Sales Exceeding Threshold
RoyaltyFeePercentOfSalesExceedingThreshold
|
0.029 | pure |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-9336000 | USD | |
| CY2013 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-29258000 | USD |
| CY2012 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17597000 | USD |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.27 | ||
| CY2013 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.39 | |
| CY2012 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.04 | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
33963901 | shares | |
| CY2013 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
20995887 | shares |
| CY2012 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
16707599 | shares |
| us-gaap |
Revenues
Revenues
|
3105000 | USD | |
| CY2013 | us-gaap |
Revenues
Revenues
|
4873000 | USD |
| CY2012 | us-gaap |
Revenues
Revenues
|
5349000 | USD |
| us-gaap |
Cost Of Revenue
CostOfRevenue
|
1442000 | USD | |
| CY2012 | us-gaap |
Royalty Expense
RoyaltyExpense
|
USD | |
| CY2014 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><strong>NOTE <font>1</font> - DESCRIPTION OF BUSINESS</strong></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-indent: 0in;"> </p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;"><strong>a.      General</strong></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;"><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px; text-align: justify;">InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex coronary and vascular disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Company's coronary products combining MicroNet and a bare-metal stent (MGuard Prime™ EPS) are marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). In October 2014, the Company launched a limited market release of its carotid embolic prevention system (CGuard™ EPS), which combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. A coronary stent product incorporating a drug-eluting (drug-coated) stent with MicroNet is currently in development. The Company markets its products through distributors in international markets, mainly in Europe, Southeast Asia, India, Latin America and Israel, and through direct sales to hospitals in Europe.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px; text-align: justify;">  </p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;"><strong>b.      Liquidity</strong></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px; text-align: justify;"><br/><font style="font-size: 10pt;">The Company has an accumulated deficit as of December 31, 2014, as well as net losses and negative operating cash flows in recent years and the current year. The Company expects to continue incurring losses and negative cash flows from operations until its MGuard™ and CGuard™ products reach commercial profitability. Management of the Company presently anticipates that it has sufficient resources to fund operations through the second quarter of 2016.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px; text-align: justify;"><br/>Management's plans include (i) the<font style="font-family: 'Times New Roman', Times, serif;"> </font>continued commercialization of the MGuard® and CGuard products, (ii) raising<font style="font-family: 'Times New Roman', Times, serif;"> </font>capital through the sale of additional equity securities or debt and (iii) obtaining financing through strategic partnerships. There<font style="font-family: 'Times New Roman', Times, serif;"> </font>are no assurances, however, that the Company will be successful in obtaining<font style="font-family: 'Times New Roman', Times, serif;"> </font>the level of financing needed for its operations. If the Company is unsuccessful<font style="font-family: 'Times New Roman', Times, serif;"> </font>in commercializing its MGuard or CGuard products and raising capital,<font style="font-family: 'Times New Roman', Times, serif;"> </font>it may need to reduce activities, curtail or cease operations<font style="font-family: 'Times New Roman', Times, serif;">.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px;"> </p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px;"><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px; text-align: justify;">During the fourth quarter of 2014, the Company began implementing a focused spending plan. The plan included reducing the focus of clinical and development expenses related to the Company's bare metal stent product and increasing the focus on the Company's drug eluting stent product. Prior to the fourth quarter of 2014, a large portion of the Company's organization was supporting the MASTER II trial, in which the Company determined not to resume enrollment, and instead allocated resources to drug eluting stents and the CGuard platform.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px; text-align: justify;"> </p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px; text-align: justify;">During the first quarter of 2015, the board of directors approved implementing another cost reduction/focused spending plan. The plan has four components: (i) reducing headcount; (ii) limiting the focus of clinical and development expenses to only the drug eluting stent product; (iii) limiting sales and marketing expenses to only those related to the CGuard EPS stent launch; and (iv) reducing across the board all other expenses (conferences, travel, promotional expenses, executive cash salaries, director cash fees, etc.). Prior to the cost reduction plan, a large portion of the Company's organization was supporting clinical trials and promotional activities related to the Company's bare metal stent platform. The Company decided to discontinue all work and promotion (such as conferences, clinical studies, and some sales activities) related to the bare metal platform. This decision allowed the Company to eliminate certain positions that related only to these activities. In addition, the Company dramatically cut all expenses not directly related to the CGuard launch and drug eluting platform development.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px; text-align: justify;"><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px; text-align: justify;">In addition, to reduce the usage of cash, on January 5, 2015, the Company amended the employment agreements with the Company's CEO and COO, to provide that, for a limited period of time to be mutually agreed upon by the Company and the CEO and COO, each of the CEO and the COO shall receive <font>50</font>% of his base salary in cash payments, with the remaining <font>50</font>% to be paid in an equivalent amount of shares of restricted common stock, payable and granted in equal installments in accordance with the Company's normal payroll <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">practices. On February 22, 2015, the COO's employment agreement was further amended to provide that the payment arrangement described above would continue until the earlier of (i) September 30, 2015 and (ii) the Company raising an aggregate of $<font>5</font> million from investors. The Company's March 9, 2015 public offering raised in excess of $5 million and therefore the COO's payment arrangement will, by the terms of this agreement, no longer be 50% paid in restricted stock. On January 5, 2015, the Company's compensation committee amended its compensation policy for directors to provide that effective as of July 1, 2014, each director would forego any cash compensation in exchange for such number of immediately vested</font> <font>10</font> year stock options having a Black-Scholes value equal to the cash compensation otherwise due to such director under the Company's current director compensation policies.<br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;"><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;"><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;"><strong>c.      Voluntary Field Corrective Action</strong> </p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 49.65pt; text-align: justify; text-indent: 0.5in;"><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;">On April 30, 2014, the Company initiated a voluntary field corrective action (“VFA”) of its MGuard Prime EPS to address the issue of stent retention following reports of MGuard Prime stent dislodgements. On June 18, 2014, the Company received approval from the European regulatory agency to resume the manufacturing of the MGuard Prime stent with a<font style="font-size: 10pt;"> modified stent securement process. The Company also received approval to modify and re-deploy existing MGuard Prime stents that were sent to the Company by clinical and commercial sites worldwide. These products have been modified and shipped to direct hospital customers and the majority of its distributor partners, who have begun shipping modified product back into hospital accounts. The Company began shipping products to new customers in the Company's direct markets in Western Europe in October 2014. The VFA had an adverse impact on both the commercial and clinical activities relating to the MGuard Prime EPS from the date of initiation through December 31, 2014.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 49.65pt; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;"> </font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;"><font style="font-size: 10pt;">The expenses associated with the modifications that were performed as a result of the VFA are approximately $<font>326,000</font> with an additional approximate $<font>55,000</font> accrued for as of December 31, 2014 which is estimated to be incurred. These expenses were recorded in “Cost of revenues” in the year ended December 31, 2014. In addition, as a result of the VFA, the Company suspended enrollment in the MASTER II trial, which had been previously launched to support its investigational device exemption application for MGuard Prime EPS with the U.S. Food and Drug Administration (“FDA”), pending a review by the FDA of the manufacturing improvements to the MGuard Prime EPS. The FDA approved the re-commencement of the MASTER II trial in October 2014. </font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;"><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;"><font style="font-size: 10pt;">Notwithstanding FDA approval to re-commence enrollment of the Master II trial, in light of current market conditions moving toward the use of drug-eluting stents (DES) over bare-metal stents, the Company elected not to resume enrollment in the MASTER II trial. As a result of this change, the MASTER II trial will no longer be an FDA registration trial.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;"><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;"><strong>d.      Fundraising</strong></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 49.65pt; text-align: justify; text-indent: 0.5in;"> </p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;">On November 7, 2014, the Company sold <font>6,261,846</font> shares of its common stock and warrants to purchase <font>3,130,923</font> shares of common stock in a registered direct offering. See also Note 9a.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.6in; text-align: justify;"> </p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px; text-align: justify;">On March 9, 2015, the Company sold <font>34,369,675</font> shares of its common stock and warrants to purchase <font>34,369,675</font> shares of common stock in a registered direct offering. Each purchaser received a warrant to purchase <font>one</font> share of common stock for each share of common stock that it purchased in the offering. The warrants have a term of exercise of <font>5</font> years from the date of issuance and an exercise price of $<font>0.55</font>. This offering resulted in net proceeds to the Company of approximately $<font>12.5</font> million after deducting placement agent fees and other estimated offering expenses.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 57.5999984741211px; text-align: justify;"><br/></p> <p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; margin: 0px 0px 0px 57.5999984741211px; text-align: justify; text-indent: 0px;"><br/></p> </div> | |
| CY2014 | nspr |
Monthly Salary Rate To Which Employees Are Entitled
MonthlySalaryRateToWhichEmployeesAreEntitled
|
0.0833 | pure |
| us-gaap |
Postemployment Benefits Period Expense
PostemploymentBenefitsPeriodExpense
|
139000 | USD | |
| CY2013 | us-gaap |
Postemployment Benefits Period Expense
PostemploymentBenefitsPeriodExpense
|
311000 | USD |
| CY2012 | us-gaap |
Postemployment Benefits Period Expense
PostemploymentBenefitsPeriodExpense
|
177000 | USD |
| us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
168000 | USD | |
| CY2013 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
208000 | USD |
| CY2012 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
206000 | USD |
| CY2014 | us-gaap |
Defined Benefit Plans Estimated Future Employer Contributions In Next Fiscal Year
DefinedBenefitPlansEstimatedFutureEmployerContributionsInNextFiscalYear
|
206000 | USD |
| CY2010Q1 | nspr |
Royalty Fee Percent Of Sales Foreign
RoyaltyFeePercentOfSalesForeign
|
0.07 | pure |
| CY2010Q1 | nspr |
Royalty Fee Percent Of Sales Domestic Sales Under Threshold
RoyaltyFeePercentOfSalesDomesticSalesUnderThreshold
|
0.07 | pure |
| CY2010Q1 | nspr |
Royalty Fee Sales Threshold
RoyaltyFeeSalesThreshold
|
10000000 | USD |
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
180000 | USD | |
| CY2013 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
383000 | USD |
| CY2012 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
220000 | USD |
| CY2010Q1 | nspr |
Royalty Fee Percent Of Sales Exceeding Threshold
RoyaltyFeePercentOfSalesExceedingThreshold
|
0.10 | pure |
| CY2013Q3 | nspr |
Royalty Fee Percent Of Total Sales Exceeding Threshold
RoyaltyFeePercentOfTotalSalesExceedingThreshold
|
0.025 | pure |
| CY2012Q4 | us-gaap |
Loss Contingency Loss In Period
LossContingencyLossInPeriod
|
85000 | USD |
| CY2012Q4 | us-gaap |
Payments For Royalties
PaymentsForRoyalties
|
205587 | USD |
| CY2012Q4 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
|
215000 | shares |
| CY2012Q4 | us-gaap |
Share Price
SharePrice
|
8.20 | |
| CY2012Q4 | nspr |
Other Significant Part Noncash Transaction Value Of Consideration Given
OtherSignificantPartNoncashTransactionValueOfConsiderationGiven
|
1848000 | USD |
| CY2012Q4 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Capitalized Cost
ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost
|
930000 | USD |
| CY2012Q4 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
918000 | USD |
| CY2013Q3 | nspr |
Royalty Fee Percent Of Sales Under Threshold
RoyaltyFeePercentOfSalesUnderThreshold
|
0.02 | pure |
| CY2013Q3 | nspr |
Royalty Fee Sales Threshold
RoyaltyFeeSalesThreshold
|
10560000 | USD |
| CY2013Q3 | us-gaap |
Payments For Royalties
PaymentsForRoyalties
|
192000 | USD |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
38000 | USD | |
| CY2013 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
132000 | USD |
| CY2012 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
201000 | USD |
| CY2013Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
93000 | USD |
| CY2012Q4 | nspr |
Royalty Fee Percent Of Sales Domestic Sales Under Threshold
RoyaltyFeePercentOfSalesDomesticSalesUnderThreshold
|
0.029 | pure |
| CY2012Q4 | nspr |
Royalty Fee Percent Of Sales Foreign
RoyaltyFeePercentOfSalesForeign
|
0.029 | pure |
| us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
USD | ||
| CY2012 | nspr |
Expense Issuance Of Warrants
ExpenseIssuanceOfWarrants
|
USD | |
| us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
USD | ||
| nspr |
Expense Issuance Of Warrants
ExpenseIssuanceOfWarrants
|
USD | ||
| CY2012 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
USD | |
| CY2012 | us-gaap |
Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
|
21000 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1500000 | USD |
| CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
|
3790000 | USD |
| CY2012 | nspr |
Stock Issued During Period Value Share Based Compensation Expenses
StockIssuedDuringPeriodValueShareBasedCompensationExpenses
|
10554000 | USD |
| CY2012Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5386000 | USD |
| CY2013 | nspr |
Stock Issued During Period Value Share Based Compensation Expenses
StockIssuedDuringPeriodValueShareBasedCompensationExpenses
|
3839000 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
2121000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
22880000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
3238000 | USD |
| CY2013 | nspr |
Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
|
962000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
95000 | USD |
| CY2013 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
27000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
8105000 | USD |
| CY2013 | us-gaap |
Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
|
314000 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
568000 | USD |
| CY2013Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
16102000 | USD |
| us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
44000 | USD | |
| CY2011Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7160000 | USD |
| us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
280000 | USD | |
| nspr |
Stock Issued During Period Value Share Based Compensation Expenses
StockIssuedDuringPeriodValueShareBasedCompensationExpenses
|
1549000 | USD | |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8639000 | USD |
| us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
USD | ||
| us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
110000 | USD | |
| CY2013 | us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
208000 | USD |
| CY2012 | us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
120000 | USD |
| us-gaap |
Pension And Other Postretirement Benefit Contributions
PensionAndOtherPostretirementBenefitContributions
|
-69000 | USD | |
| CY2013 | us-gaap |
Pension And Other Postretirement Benefit Contributions
PensionAndOtherPostretirementBenefitContributions
|
-246000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
93000 | USD |
| CY2012 | us-gaap |
Pension And Other Postretirement Benefit Contributions
PensionAndOtherPostretirementBenefitContributions
|
-72000 | USD |
| CY2012 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
12000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
124000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
290000 | USD |
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-358000 | USD | |
| CY2013 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-13397000 | USD |
| CY2012 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
65000 | USD |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1549000 | USD | |
| CY2013 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3839000 | USD |
| CY2012 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
10554000 | USD |
| us-gaap |
Defined Benefit Plan Actuarial Gain Loss
DefinedBenefitPlanActuarialGainLoss
|
15000 | USD | |
| CY2013 | us-gaap |
Defined Benefit Plan Actuarial Gain Loss
DefinedBenefitPlanActuarialGainLoss
|
6000 | USD |
| CY2012 | us-gaap |
Defined Benefit Plan Actuarial Gain Loss
DefinedBenefitPlanActuarialGainLoss
|
1000 | USD |
| CY2013 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
918000 | USD |
| us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-17000 | USD | |
| CY2013 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
179000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
22000 | USD |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
116000 | USD | |
| CY2013 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-85000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1210000 | USD |
| us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
-1000 | USD | |
| CY2013 | us-gaap |
Increase Decrease In Retail Related Inventories
IncreaseDecreaseInRetailRelatedInventories
|
-63000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Retail Related Inventories
IncreaseDecreaseInRetailRelatedInventories
|
-19000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-151000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
273000 | USD |
| us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
737000 | USD | |
| CY2013 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
390000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-322000 | USD |
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-10000 | USD | |
| CY2012 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
10000 | USD |
| us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
-163000 | USD | |
| CY2013 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
-30000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
228000 | USD |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-6799000 | USD | |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-10300000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-8580000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
56000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
-306000 | USD |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
180000 | USD | |
| CY2013 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
202000 | USD |
| us-gaap |
Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
|
72000 | USD | |
| CY2013 | us-gaap |
Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
|
118000 | USD |
| CY2012 | us-gaap |
Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
|
71000 | USD |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-252000 | USD | |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-376000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-43000 | USD |
| CY2013 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
2121000 | USD |
| CY2013 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
22880000 | USD |
| CY2012 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
1132000 | USD |
| CY2012 | nspr |
Proceeds From Convertible Loan And Warrants Net Of Issuance Costs
ProceedsFromConvertibleLoanAndWarrantsNetOfIssuanceCosts
|
9868000 | USD |
| CY2013 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1057000 | USD |
| CY2012 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1500000 | USD |
| CY2012 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
281000 | USD |
| us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
237000 | USD | |
| us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
9763000 | USD | |
| CY2012 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
21000 | USD |
| CY2013 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
27000 | USD |
| CY2013 | us-gaap |
Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
|
8787000 | USD |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
9763000 | USD | |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
15123000 | USD |
| us-gaap |
Increase Decrease In Retail Related Inventories
IncreaseDecreaseInRetailRelatedInventories
|
USD | ||
| CY2013 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
78000 | USD |
| CY2012 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
17000 | USD |
| us-gaap |
Interest Paid
InterestPaid
|
111000 | USD | |
| CY2013 | us-gaap |
Interest Paid
InterestPaid
|
745000 | USD |
| CY2012 | us-gaap |
Interest Paid
InterestPaid
|
225000 | USD |
| CY2013 | nspr |
Significant Noncash Transaction Value Of Royalties Buyout
SignificantNoncashTransactionValueOfRoyaltiesBuyout
|
930000 | USD |
| nspr |
Noncash Investing And Financing Activity Change In Funds And Liabilities In Respect Of Employee Rights Upon Retirement
NoncashInvestingAndFinancingActivityChangeInFundsAndLiabilitiesInRespectOfEmployeeRightsUponRetirement
|
59000 | USD | |
| us-gaap |
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
90000 | USD | |
| CY2012 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
11066000 | USD |
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
3000 | USD | |
| CY2013 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
89000 | USD |
| CY2012 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-229000 | USD |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
2715000 | USD | |
| CY2013 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
4536000 | USD |
| CY2012 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
2214000 | USD |
| CY2013Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14820000 | USD |
| CY2012Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
10284000 | USD |
| CY2011Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8070000 | USD |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
17535000 | USD |
| us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
8000 | USD | |
| CY2013 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
USD | |
| CY2012 | us-gaap |
Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
|
USD | |
| us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
USD | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
USD | ||
| CY2013 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
USD | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
USD | ||
| CY2012 | us-gaap |
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
USD | |
| CY2013 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
USD | |
| CY2012 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
USD | |
| nspr |
Proceeds From Convertible Loan And Warrants Net Of Issuance Costs
ProceedsFromConvertibleLoanAndWarrantsNetOfIssuanceCosts
|
USD | ||
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
USD | ||
| CY2012 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
USD | |
| CY2012 | nspr |
Noncash Investing And Financing Activity Change In Funds And Liabilities In Respect Of Employee Rights Upon Retirement
NoncashInvestingAndFinancingActivityChangeInFundsAndLiabilitiesInRespectOfEmployeeRightsUponRetirement
|
USD | |
| us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
USD | ||
| us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
USD | ||
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
USD | ||
| CY2012 | nspr |
Significant Noncash Transaction Value Of Royalties Buyout
SignificantNoncashTransactionValueOfRoyaltiesBuyout
|
USD | |
| us-gaap |
Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
|
USD | ||
| us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
USD | ||
| nspr |
Significant Noncash Transaction Value Of Royalties Buyout
SignificantNoncashTransactionValueOfRoyaltiesBuyout
|
USD | ||
| CY2013 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
USD | |
| CY2013 | nspr |
Noncash Investing And Financing Activity Change In Funds And Liabilities In Respect Of Employee Rights Upon Retirement
NoncashInvestingAndFinancingActivityChangeInFundsAndLiabilitiesInRespectOfEmployeeRightsUponRetirement
|
USD | |
| CY2012 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
USD | |
| CY2013 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
USD | |
| CY2013 | us-gaap |
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
USD | |
| CY2012 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
USD | ||
| CY2013 | nspr |
Proceeds From Convertible Loan And Warrants Net Of Issuance Costs
ProceedsFromConvertibleLoanAndWarrantsNetOfIssuanceCosts
|
USD | |
| CY2012Q4 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.25 | pure |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
6300000 | USD |
| CY2014Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
USD | |
| CY2013Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
93000 | USD |
| CY2014Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
635000 | USD |
| CY2013Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1855000 | USD |
| CY2014Q4 | us-gaap |
Nontrade Receivables Current
NontradeReceivablesCurrent
|
359000 | USD |
| CY2013Q4 | us-gaap |
Nontrade Receivables Current
NontradeReceivablesCurrent
|
387000 | USD |
| CY2014Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
150000 | USD |
| CY2013Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
141000 | USD |
| CY2014Q4 | us-gaap |
Inventory Net
InventoryNet
|
1924000 | USD |
| CY2013Q4 | us-gaap |
Inventory Net
InventoryNet
|
1593000 | USD |
| CY2014Q4 | us-gaap |
Assets Current
AssetsCurrent
|
9368000 | USD |
| CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
21604000 | USD |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
622000 | USD |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
652000 | USD |
| CY2014Q4 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
153000 | USD |
| CY2013Q4 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
310000 | USD |
| CY2014Q4 | us-gaap |
Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
|
498000 | USD |
| CY2013Q4 | us-gaap |
Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
|
434000 | USD |
| CY2014Q4 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
66000 | USD |
| CY2013Q4 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
114000 | USD |
| CY2014Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
752000 | USD |
| CY2013Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
852000 | USD |
| CY2014Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1469000 | USD |
| CY2013Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1710000 | USD |
| CY2014Q4 | us-gaap |
Assets
Assets
|
11459000 | USD |
| CY2013Q4 | us-gaap |
Assets
Assets
|
23966000 | USD |
| CY2014Q4 | us-gaap |
Accounts Payable Trade Current
AccountsPayableTradeCurrent
|
909000 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable Trade Current
AccountsPayableTradeCurrent
|
1623000 | USD |
| CY2014Q4 | us-gaap |
Accounts Payable Other Current
AccountsPayableOtherCurrent
|
3576000 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable Other Current
AccountsPayableOtherCurrent
|
3141000 | USD |
| CY2014Q4 | us-gaap |
Customer Advances Current
CustomerAdvancesCurrent
|
179000 | USD |
| CY2013Q4 | us-gaap |
Customer Advances Current
CustomerAdvancesCurrent
|
179000 | USD |
| CY2014Q4 | us-gaap |
Loans Payable Current
LoansPayableCurrent
|
3809000 | USD |
| CY2013Q4 | us-gaap |
Loans Payable Current
LoansPayableCurrent
|
1181000 | USD |
| CY2014Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
8473000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
6124000 | USD |
| CY2014Q4 | us-gaap |
Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
|
687000 | USD |
| CY2013Q4 | us-gaap |
Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
|
610000 | USD |
| CY2014Q4 | us-gaap |
Long Term Loans Payable
LongTermLoansPayable
|
5086000 | USD |
| CY2013Q4 | us-gaap |
Long Term Loans Payable
LongTermLoansPayable
|
8593000 | USD |
| CY2014Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
5773000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
9203000 | USD |
| CY2014Q4 | us-gaap |
Liabilities
Liabilities
|
14246000 | USD |
| CY2013Q4 | us-gaap |
Liabilities
Liabilities
|
15327000 | USD |
| CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | USD |
| CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | USD |
| CY2014Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
104620000 | USD |
| CY2013Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
90952000 | USD |
| CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-107411000 | USD |
| CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-82316000 | USD |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2787000 | USD |
| CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
11459000 | USD |
| CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
23966000 | USD |
| CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
125000000 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
41368889 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
33983346 | shares |
| CY2014 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
2034000 | USD |
| CY2014 | us-gaap |
Gross Profit
GrossProfit
|
784000 | USD |
| CY2014 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.71 | |
| CY2014 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-1220000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
-28000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Retail Related Inventories
IncreaseDecreaseInRetailRelatedInventories
|
USD | |
| CY2014 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
331000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-659000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
USD | |
| CY2014 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
626000 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-19362000 | USD |
| CY2014 | us-gaap |
Inventory Recall Expense
InventoryRecallExpense
|
326000 | USD |
| CY2014 | us-gaap |
Royalty Expense
RoyaltyExpense
|
USD | |
| us-gaap |
Royalty Expense
RoyaltyExpense
|
USD | ||
| CY2014 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8744000 | USD |
| CY2014 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
6613000 | USD |
| CY2014 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
9125000 | USD |
| CY2014 | us-gaap |
Operating Expenses
OperatingExpenses
|
24482000 | USD |
| CY2014 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-23698000 | USD |
| CY2014 | us-gaap |
Nonoperating Gains Losses
NonoperatingGainsLosses
|
24000 | USD |
| CY2014 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1385000 | USD |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-499000 | USD | |
| CY2013 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-14177000 | USD |
| CY2012 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-38000 | USD |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-25083000 | USD |
| CY2014 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
12000 | USD |
| CY2014 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
35393644 | shares |
| CY2014 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-25095000 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
9646000 | USD |
| CY2014 | nspr |
Stock Issued During Period Value Share Based Compensation Expenses
StockIssuedDuringPeriodValueShareBasedCompensationExpenses
|
4138000 | USD |
| CY2014 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
115000 | USD |
| CY2014 | us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
263000 | USD |
| CY2014 | us-gaap |
Pension And Other Postretirement Benefit Contributions
PensionAndOtherPostretirementBenefitContributions
|
-77000 | USD |
| CY2014 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-350000 | USD |
| CY2014 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4138000 | USD |
| CY2014 | us-gaap |
Defined Benefit Plan Actuarial Gain Loss
DefinedBenefitPlanActuarialGainLoss
|
18000 | USD |
| CY2014 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
USD | |
| CY2014 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-39000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
-93000 | USD |
| CY2014 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
133000 | USD |
| CY2014 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
USD | |
| CY2014 | us-gaap |
Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
|
46000 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-86000 | USD |
| CY2014 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
9535000 | USD |
| CY2014 | nspr |
Proceeds From Convertible Loan And Warrants Net Of Issuance Costs
ProceedsFromConvertibleLoanAndWarrantsNetOfIssuanceCosts
|
USD | |
| CY2014 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
USD | |
| CY2014 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
1148000 | USD |
| CY2014 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
USD | |
| CY2014 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
USD | |
| CY2014 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
115000 | USD |
| CY2014 | us-gaap |
Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
|
USD | |
| CY2014 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
8272000 | USD |
| CY2014 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-59000 | USD |
| CY2014 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-11235000 | USD |
| CY2014 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
14000 | USD |
| CY2014 | us-gaap |
Interest Paid
InterestPaid
|
1082000 | USD |
| CY2014 | nspr |
Significant Noncash Transaction Value Of Royalties Buyout
SignificantNoncashTransactionValueOfRoyaltiesBuyout
|
USD | |
| CY2014 | nspr |
Noncash Investing And Financing Activity Change In Funds And Liabilities In Respect Of Employee Rights Upon Retirement
NoncashInvestingAndFinancingActivityChangeInFundsAndLiabilitiesInRespectOfEmployeeRightsUponRetirement
|
USD | |
| CY2014 | us-gaap |
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
USD | |
| CY2014 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
881000 | USD |
| CY2012 | us-gaap |
Depreciation
Depreciation
|
120000 | USD |
| CY2013Q4 | nspr |
Registration Payment Arrangement Maximum Amount Of Offering
RegistrationPaymentArrangementMaximumAmountOfOffering
|
40000000 | USD |
| CY2013Q4 | nspr |
Registration Payment Arrangement Commission Rate
RegistrationPaymentArrangementCommissionRate
|
0.03 | pure |
| CY2014Q4 | us-gaap |
Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
|
55000 | USD |
| CY2014Q4 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
6261846 | shares |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1364000 | USD |
| CY2013Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
712000 | USD |
| CY2014Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
875000 | USD |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1497000 | USD |
| CY2014 | us-gaap |
Depreciation
Depreciation
|
163000 | USD |
| us-gaap |
Depreciation
Depreciation
|
78000 | USD | |
| CY2013 | us-gaap |
Depreciation
Depreciation
|
162000 | USD |
| CY2014 | us-gaap |
Postemployment Benefits Period Expense
PostemploymentBenefitsPeriodExpense
|
233000 | USD |
| CY2014 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
285000 | USD |
| CY2014Q4 | nspr |
Other Payables Related Parties Current
OtherPayablesRelatedPartiesCurrent
|
241000 | USD |
| CY2013Q4 | nspr |
Other Payables Related Parties Current
OtherPayablesRelatedPartiesCurrent
|
355000 | USD |
| CY2014 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
388000 | USD |
| CY2014 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
148000 | USD |
| CY2014Q4 | nspr |
Shares Authorized
SharesAuthorized
|
130000000 | shares |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
| CY2013Q1 | us-gaap |
Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
|
178029 | shares |
| CY2013Q2 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
12500000 | shares |
| CY2013Q2 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
2.00 | |
| CY2013Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
22600000 | USD |
| CY2014Q4 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
1.30 | |
| CY2014Q4 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
7400000 | USD |
| CY2014Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
6769189 | shares |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y5M23D | |
| CY2014 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
|
P6Y9M7D | |
| CY2014Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
3683402 | shares |
| CY2014Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
230817 | USD |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
0 | USD |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
177000 | USD | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.78 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.47 | ||
| CY2014Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
3900000 | USD |
| CY2014 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y4D | |
| CY2014 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4138000 | USD |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1549000 | USD | |
| CY2013 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3839000 | USD |
| CY2012 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
10554000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-9945000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-8529000 | USD |
| us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-3171000 | USD | |
| CY2012 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-5984000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
390000 | USD |
| us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
164000 | USD | |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
1613000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
1448000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
2038000 | USD |
| us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
-171000 | USD | |
| CY2013 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
205000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
-75000 | USD |
| CY2014 | us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
USD | |
| us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
USD | ||
| CY2013 | us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
USD | |
| CY2012 | us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
-71000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
-73000 | USD |
| us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
-14000 | USD | |
| CY2013 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
-61000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
1408000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
|
USD | |
| us-gaap |
Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
|
-121000 | USD | |
| CY2013 | us-gaap |
Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
|
USD | |
| CY2012 | us-gaap |
Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
|
-245000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
5086000 | USD |
| us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
3323000 | USD | |
| CY2013 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
8196000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
3533000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
19569000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
16246000 | USD |
| CY2012Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
8050000 | USD |
| CY2011Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
4517000 | USD |
| CY2014 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
5086000 | USD |
| us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
3323000 | USD | |
| CY2013 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
8196000 | USD |
| CY2012 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
3533000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
24655000 | USD |
| CY2011Q2 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
71000 | USD |
| CY2012 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
|
71000 | USD |
| CY2012Q2 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
USD | |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
|
89000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
|
107000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
|
59000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
|
85000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Gross Current
DeferredTaxAssetsGrossCurrent
|
148000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Gross Current
DeferredTaxAssetsGrossCurrent
|
192000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
|
1738000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
|
1085000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2990000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2137000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
19729000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
16111000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments
|
50000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments
|
44000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
|
24507000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
|
19377000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
USD | |
| CY2014Q4 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
972000 | USD |
| CY2013Q4 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
2260000 | USD |
| CY2014Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
337000 | USD |
| CY2013Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
405000 | USD |
| CY2014Q4 | us-gaap |
Government Contract Receivable
GovernmentContractReceivable
|
162000 | USD |
| CY2013Q4 | us-gaap |
Government Contract Receivable
GovernmentContractReceivable
|
221000 | USD |
| CY2014Q4 | us-gaap |
Advances On Inventory Purchases
AdvancesOnInventoryPurchases
|
180000 | USD |
| CY2013Q4 | us-gaap |
Advances On Inventory Purchases
AdvancesOnInventoryPurchases
|
152000 | USD |
| CY2014Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
17000 | USD |
| CY2013Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
14000 | USD |
| CY2014 | nspr |
Allowance For Doubtful Accounts Receivable Current Changes From Exchange Rate Differences
AllowanceForDoubtfulAccountsReceivableCurrentChangesFromExchangeRateDifferences
|
-46000 | USD |
| CY2012 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
1322000 | USD |
| nspr |
Allowance For Doubtful Accounts Receivable Current Changes From Exchange Rate Differences
AllowanceForDoubtfulAccountsReceivableCurrentChangesFromExchangeRateDifferences
|
18000 | USD | |
| CY2014Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
1273000 | USD |
| CY2013Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
1097000 | USD |
| CY2013Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
329000 | USD |
| CY2014 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
35000 | USD |
| CY2014Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
326000 | USD |
| CY2014 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
47000 | USD |
| us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
-200000 | USD | |
| CY2013Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
341000 | USD |
| CY2013Q4 | us-gaap |
Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
|
155000 | USD |
| CY2013 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
-64000 | USD |
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
40000 | USD | |
| CY2013 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
0 | USD |
| CY2012 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
443000 | USD |
| CY2014Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
1022000 | USD |
| CY2013Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
1133000 | USD |
| CY2014Q4 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
410000 | USD |
| CY2013Q4 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
325000 | USD |
| CY2014Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1016000 | USD |
| CY2013Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
622000 | USD |
| CY2014Q4 | us-gaap |
Accrued Sales Commission Current
AccruedSalesCommissionCurrent
|
120000 | USD |
| CY2013Q4 | us-gaap |
Accrued Sales Commission Current
AccruedSalesCommissionCurrent
|
139000 | USD |
| CY2014Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
993000 | USD |
| CY2013Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
886000 | USD |
| CY2014Q4 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
15000 | USD |
| CY2013Q4 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
36000 | USD |
| CY2014 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
43000 | USD |
| us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
27000 | USD | |
| CY2013 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
38000 | USD |
| CY2012 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
50000 | USD |
| CY2014 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2000 | USD |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2000 | USD | |
| CY2013 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
28000 | USD |
| CY2012 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
40000 | USD |
| CY2014 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
18000 | USD |
| us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-1000 | USD | |
| CY2013 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
63000 | USD |
| CY2012 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-112000 | USD |
| CY2013 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-9330000 | USD |
| CY2013 | nspr |
Expense Issuance Of Warrants
ExpenseIssuanceOfWarrants
|
568000 | USD |
| CY2014 | us-gaap |
Interest Expense
InterestExpense
|
1409000 | USD |
| CY2014 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
USD | |
| CY2014 | nspr |
Expense Issuance Of Warrants
ExpenseIssuanceOfWarrants
|
USD | |
| CY2012 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
78000 | USD |
| CY2013 | us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
142000 | USD |
| CY2013 | nspr |
Allowance For Doubtful Accounts Receivable Current Changes From Exchange Rate Differences
AllowanceForDoubtfulAccountsReceivableCurrentChangesFromExchangeRateDifferences
|
11000 | USD |
| CY2012 | nspr |
Allowance For Doubtful Accounts Receivable Current Changes From Exchange Rate Differences
AllowanceForDoubtfulAccountsReceivableCurrentChangesFromExchangeRateDifferences
|
-18000 | USD |
| CY2014Q4 | us-gaap |
Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
|
325000 | USD |
| CY2014 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
129000 | USD |
| CY2014Q4 | nspr |
Percentage Of Compensation Payable In Cash
PercentageOfCompensationPayableInCash
|
0.5 | pure |
| CY2014 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
4600000 | USD |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
800000 | USD |
| CY2014 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.98 | |
| CY2014 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2014 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
4.24 | |
| CY2014 | nspr |
Income Tax Reconciliation Revenues
IncomeTaxReconciliationRevenues
|
1100000 | USD |
| CY2014 | us-gaap |
Revenues
Revenues
|
2818000 | USD |
| CY2014 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2014 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2014 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-12-31 | |
| CY2014 | dei |
Trading Symbol
TradingSymbol
|
NSPR | |
| CY2013 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
245000 | USD |
| CY2014 | dei |
Entity Registrant Name
EntityRegistrantName
|
InspireMD, Inc. | |
| CY2014 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001433607 | |
| CY2015Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
78152015 | shares |
| CY2014 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | |
| CY2014 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2014 | dei |
Document Type
DocumentType
|
10-K | |
| CY2014Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
41368889 | shares |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
881000 | USD |
| CY2012Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
215000 | USD |
| CY2011Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
155000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
USD | |
| nspr |
Income Tax Reconciliation Revenues
IncomeTaxReconciliationRevenues
|
USD | ||
| CY2013 | nspr |
Income Tax Reconciliation Revenues
IncomeTaxReconciliationRevenues
|
USD | |
| CY2012 | nspr |
Income Tax Reconciliation Revenues
IncomeTaxReconciliationRevenues
|
USD | |
| CY2014 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" width="100%" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;"> <tr style="vertical-align: top;"> <td style="width: 51.05pt;"></td> <td style="width: 19.85pt;"><font style="font-family: 'Times New Roman', Times, serif;"><b>a.</b></font></td> <td style="padding-right: 1.15pt;"><font style="font-family: 'Times New Roman', Times, serif;"><b>Use of estimates</b></font></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 1.15pt 0px 70.9pt; text-indent: -19.85pt;"><font style="font-family: 'Times New Roman', Times, serif;"><b> </b></font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 70pt; text-align: justify;"><font style="font-family: 'Times New Roman', Times, serif;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those estimates.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 70pt; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'Times New Roman', Times, serif;"> </font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 70pt; text-align: justify;"><font style="font-family: 'Times New Roman', Times, serif;">As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations, royalty buyout, legal contingencies and estimation of the fair value of warrants.</font></p> </div> | |
| us-gaap |
Advertising Expense
AdvertisingExpense
|
800000 | USD | |
| CY2013 | us-gaap |
Advertising Expense
AdvertisingExpense
|
1100000 | USD |
| CY2012 | us-gaap |
Advertising Expense
AdvertisingExpense
|
600000 | USD |
| CY2014 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13523260 | shares |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8431252 | shares | |
| CY2014 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; width: 1887px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 51.05pt; text-align: right;"></td> <td style="width: 19.85pt;"><font style="font-family: 'Times New Roman', Times, serif;"><b>f.</b></font></td> <td style="text-align: justify;"><font style="font-family: 'Times New Roman', Times, serif;"><b>Concentration of credit risk and allowance for doubtful accounts</b></font></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: left; text-indent: 0.5in;"><font style="font-family: 'Times New Roman', Times, serif;"> </font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0in; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 1.15pt 0px 70pt; text-align: justify;"><font style="font-family: 'Times New Roman', Times, serif;">Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, which are deposited in major financially sound institutions in the U.S, Israel, Germany and the United Kingdom, and trade accounts receivable. The Company's trade accounts receivable are derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers' financial condition and, generally, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is<b> </b>unable to meet its financial obligations to the Company, the Company provides an allowance for credit losses to reduce the receivable to the amount management reasonably believes will be collected, which is netted against "Accounts receievable- Trade".</font></p> </div> | |
| us-gaap |
Stock Issued1
StockIssued1
|
USD | ||
| CY2013 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8006837 | shares |
| CY2012 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8117577 | shares |
| CY2014 | us-gaap |
Stock Issued1
StockIssued1
|
110000 | USD |
| CY2013 | us-gaap |
Stock Issued1
StockIssued1
|
USD | |
| CY2014 | us-gaap |
Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
|
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" width="100%" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;"> <tr style="vertical-align: top;"> <td style="width: 51.05pt;"></td> <td style="width: 19.85pt;"><b>u.</b></td> <td style="text-align: justify;"><b>Embedded derivatives</b></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 70.9pt; text-align: justify; text-indent: -19.85pt;"><b> </b></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 70pt; text-align: justify; text-indent: 0.9pt;">Embedded derivatives in debt contracts that are not clearly and closely related to the host debt are bifurcated and accounted for separately. Those embedded derivatives are measured at fair value each reporting date, with changes in fair value recorded in earnings. See Note 6.</p> </div> | |
| CY2014 | us-gaap |
Advertising Expense
AdvertisingExpense
|
800000 | USD |
| CY2014Q4 | nspr |
Percentage Of Compensation Payable In Stock
PercentageOfCompensationPayableInStock
|
0.5 | pure |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
|
P10Y | |
| CY2015Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
34369675 | shares |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
12500000 | USD |
| CY2014Q4 | nspr |
Funding Threshold At Which Cost Savings Plan Is Discontinued
FundingThresholdAtWhichCostSavingsPlanIsDiscontinued
|
5000000 | USD |
